Marker Therapeutics Announces FDA Clearance Of IND For MT-601
Marker Therapeutics Announces FDA Clearance Of IND For MT-601
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for MT-601, a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens, for the treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with front-line chemotherapy.
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for MT-601, a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens, for the treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with front-line chemotherapy.
亞洲網加利福尼亞州聖何塞10月24日電MARKER治療公司(納斯達克代碼:MRKR)是一家臨牀階段的免疫腫瘤學公司,專門開發用於治療血液惡性腫瘤和實體腫瘤適應症的下一代基於T細胞的免疫療法。該公司今天宣佈,美國食品和藥物管理局已經批准了該公司的研究新藥申請。MT-601是一種針對六種抗原的多腫瘤相關抗原(MultiTAA)特異性T細胞產品,用於治療局部晚期不可切除或轉移性胰腺癌患者,並結合一線化療。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧